& Events
& Events
News
& Events
Aug 10, 2023 Novo Nordisk to acquire Inversago Pharma to develop new therapies for people living with obesity, diabetes and other serious metabolic diseases
Bagsværd, Denmark and Montreal, Canada, 10 August 2023 – Novo Nordisk A/S and Inversago Pharma today announced that Novo Nordisk has agreed to acquire Inversago for up to 1.075 billion US dollars in cash if certain development and commercial milestones are achieved. Inversago Pharma is a private, Montreal-based developer of CB1 receptor-based therapies for the […]
Jun 23, 2023 Inversago Pharma Presents Data from Phase 1b Trial of INV-202, a Peripheral CB1r Blocker for Metabolic Syndrome, at the 83rd American Diabetes Association Scientific Sessions
-Study results demonstrated favorable safety, tolerability, and PK profile -Clinically significant weight loss was observed in only 28 days -Positive trends in lipids and glucose effects were also shown Montreal, Canada and San Diego, CA – June 23, 2023 – Inversago Pharma Inc. (“Inversago”), a leader in the development of peripherally-acting CB1 receptor (CB1r) blockers […]
Jun 8, 2023 Inversago Pharma to Present Data from Phase 1b Trial of INV-202, a Peripheral CB1r Blocker for Metabolic Syndrome, at the 83rd American Diabetes Association Scientific Sessions
Montreal, Canada – June 8, 2023 – Inversago Pharma Inc. (“Inversago”), a leader in the development of peripherally-acting CB1 receptor blockers to address complications associated with metabolic and fibrotic diseases, today announced that it will present data from the Phase 1b trial for INV-202, at the 83rd American Diabetes Association Scientific Sessions taking place on […]
May 22, 2023 Inversago Pharma Announces New Data to be Presented at the 2023 American Thoracic Society International Conference
INV-202 Induces Weight Loss and Reduces Airway Hyperreactivity in Mouse Model of Obese Asthma Montreal, Canada– May 22, 2023 – Inversago Pharma Inc. (“Inversago”), a leader in the development of peripherally-acting CB1 receptor (CB1r) blockers to address complications associated with metabolic and fibrotic diseases, today announced positive results from a proof-of-concept study of INV-202 in […]
